Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
Overview
To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)
Full Title of Study: “Effects on the Emergence and Transmission of Vancomycin-Resistant Enterococci After Changes in Antibiotic Use in a Hematology Unit.”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
Interventions
- Drug: Piperacillin/tazobactam and other β-lactam/β-lactamase
Participating in This Clinical Trial
Inclusion Criteria
- All patients admitted to or transferred to the SICU. – Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU. – Provide written informed consent Exclusion Criteria:
- Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors. – Females who are pregnant and breast feeding – Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours. – Those who have already been participating other clinical study related with antibiotics.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Overall Official(s)
- Medical Monitor, Study Director, Wyeth is now a wholly owned subsidiary of Pfizer
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.